Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of polypeptide and its application

A drug and pharmaceutical technology, applied in the field of peptides, can solve the problems of single pharmacological target, high toxicity of chemical drugs, low safety, etc., and achieve the effect of reducing expression content, improving lung tissue structure, and high safety.

Active Publication Date: 2022-05-20
NANJING ANJI BIOLOGICAL TECH CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0027] Most of the existing drugs for the treatment of fibrosis are chemical drugs, which have problems such as high toxicity, low safety, and single pharmacological target

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of polypeptide and its application
  • A kind of polypeptide and its application
  • A kind of polypeptide and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Embodiment 1, pulmonary fibrosis animal model

[0064] Experimental animals and materials:

[0065] 1. Experimental animals:

[0066] Source, Species, Strain: SPF grade, SD rats, purchased from Shanghai Sipro-Bikay Laboratory Animal Co., Ltd.

[0067] Provided (Experimental Animal License: SCXK (Shanghai) 2013-0016)

[0068] Weight: 180-200g at the time of purchase, 180-220g at the beginning of modeling

[0069] Gender: Male.

[0070] Number of animals in each group: 14 in each group.

[0071] 2. Experimental materials:

[0072]

[0073] 3. Experimental method:

[0074] SD rats were anesthetized by intraperitoneal injection of 1 mL / 100 g and 4% chloral hydrate. After the rats were anesthetized, the rats were fixed, and the necks of the rats were disinfected with 75% alcohol cotton. Cut the rat neck skin longitudinally with scissors, and bluntly tear the fascia and muscles longitudinally with forceps to expose the trachea. A syringe was inserted into the trach...

Embodiment 2

[0086] Example 2. Establishment of In Vitro Liver Fibrosis Model and Peptide Therapy

[0087] 1. Experimental materials:

[0088] Alkaline HYP Kit Manufacturer: Nanjing Jiancheng

[0089] 2. Experimental method:

[0090] Culture LX-2 cells with 1640 medium containing 10% FBS, and place it at 37°C, 5% CO 2 Cultured in an incubator, the medium was changed every 2 days, and the cells were passaged according to the density of the cells. Take the LX-2 cells in the logarithmic growth phase, digest them with 0.25% trypsin, make a cell suspension, and adjust the cell density to 4×10 5 cells / mL, inoculate them in 96-well plates, 100 μL per well, culture overnight, add TGF-β1 the next day to induce the proliferation and activation of LX-2 cells, and give peptide drugs 1 μmol / L at the same time, except for the blank group, no TGF-β1 was added. β1 and other groups were added with TGF-β1 (10ng / mL), cultured in the incubator for 48h, then added 10μL of MTT to each well, sucked out the M...

Embodiment 3

[0100] Embodiment 3, establishment of renal fibrosis model

[0101] 1. Experimental animals

[0102] Clean-grade male SD rats were purchased from Nanjing Qinglongshan Animal Farm, with a body weight of 180-200g when purchased, 190-210g when the model was started, and 180-200g when the drug was started.

[0103] 2. Experimental materials:

[0104] Normal saline Manufacturer: Anhui Double Crane Pharmaceutical Co., Ltd.

[0105] Rat TGF-β1 ELISA Kit Manufacturer: Tianjin Anoricang Biotechnology Co., Ltd.

[0106] Alkaline HYP Kit Manufacturer: Nanjing Jiancheng

[0107] 3. Experimental method

[0108] To establish an animal model of renal fibrosis, SD rats were anesthetized with 4% chloral hydrate, intraperitoneally injected with 1mL / 100g, fixed on the operating board, and the operating area was sterilized for later use, about 3- Cut open the abdominal cavity at 4 mm, and the surgical team treated the left kidney and ureter, ligated and separated the ureter near the lower po...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a polypeptide and belongs to the field of biopharmaceuticals. 1. A polypeptide, characterized in that, the structural domain Pro-Arg-Cys-X-Y-Gly-Glu contained in the polypeptide, wherein X is Trp or Tyr; Y is Arg or Cys; and Arg-Gly-Ala- Asp-Arg-Ala; or the sequence after mutating any amino acid in the above domain; can treat various fibrotic diseases and conditions, including pulmonary fibrosis, liver fibrosis, bone marrow fibrosis, renal fibrosis and myocardial fibrosis , skin fibrosis and lung tissue lesions.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and more specifically relates to a polypeptide that can be used to prevent or treat various fibrotic diseases. And anti-myocardial fibrosis, anti-skin fibrosis. Background technique [0002] Fibrosis is defined as the excessive deposition of extracellular matrix (ECM) components such as fibronectin (FN) and type I collagen (COLI) by organ fibroblasts. Organ fibrosis is the final common pathway of many diseases leading to end organ failure. Uncontrollable wound healing responses, including acute and chronic inflammation, angiogenesis, activation of fibroblasts, and remodeling of the extracellular matrix, are involved in the pathogenesis of fibrosis. At present, the pathogenesis, diagnosis methods and prevention and treatment measures of organ or tissue fibrosis have been extensively studied. In the existing technology, although considerable progress has been made in some aspects, there are stil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/06C07K19/00A61K38/08A61P11/00A61P1/16A61P9/00A61P17/00A61P19/08
CPCC07K7/08A61P11/00A61P1/16A61P9/00A61P17/00A61P19/08A61K38/00A61P31/04A61K38/10A61P13/12C07K7/06
Inventor 康志安
Owner NANJING ANJI BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com